Abbott's Q4 2024: Sales Surge Driven by Health Focus, Diabetes Care, and Medtech Innovations

Strong Financial Performance:
- Abbott Laboratories reported a sales growth of 9.5% in 2024, excluding COVID testing, and a 13% increase in adjusted earnings per share for Q4 2024 compared to the prior year.
- The growth was driven by increased health and wellness focus, innovation in diagnostic tests, and strong performance in treatment areas like pharma and med tech.

Growth Across Segments:
- Nutrition sales increased by 7% in Q4, driven by adult nutrition growth, particularly in Ensure and Glucerna brands, with adult nutrition products growing 9% in 2024.
- Diagnostics saw a 6% increase, excluding COVID testing, led by rapid diagnostics, and EPD sales grew by 8.5%, demonstrating broad-based growth across markets and therapeutic areas.

Diabetes Care and Continuous Glucose Monitors:
- Sales of continuous glucose monitors reached $1.8 billion in Q4 2024, representing a 23% growth, with full-year sales of approximately $6.5 billion, up 22%.
- Growth was attributed to increased adoption and market share expansion in the U.S., driven by products like Libre.

Medtech and Structural Heart Growth:
- Medical devices sales grew 14%, with strong performance in Structural Heart, which grew 23%, driven by surgical valves, interventions, and transcatheter products.
- The comprehensive portfolio and market-led products, including MitraClip and TriClip, supported this growth, as well as innovation in the transcatheter repair segment.